Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26632876 | 0.83 | ALDH1A1 (0.34) | LMNATP53CYP1A2CYP3A4MAPT | |
| SCHEMBL27869252 | 0.82 | ALDH1A1 (0.38) | LMNATP53CYP1A2CYP3A4MAPT | |
| SCHEMBL27593860 | 0.82 | HSD17B10 (0.38) | LMNATP53CYP1A2CYP3A4MAPT | |
| SCHEMBL25741032 | 0.80 | LMNA (0.32) | LMNATP53CYP1A2CYP3A4MAPT | |
| SCHEMBL30525098 | 0.79 | MAPK1 (0.39) | LMNATP53CYP1A2CYP3A4MAPT | |
| SCHEMBL1387795 | 0.79 | MAPT (0.39) | LMNATP53CYP1A2CYP3A4MAPT | |
| SCHEMBL6760184 | 0.79 | MAPK1 (0.39) | LMNATP53CYP1A2CYP3A4MAPT | |
| SCHEMBL18691989 | 0.79 | LMNA (0.41) | LMNATP53CYP1A2CYP3A4MAPT | |
| SCHEMBL146501 | 0.79 | LMNA (0.41) | LMNATP53CYP1A2CYP3A4MAPT | |
| SCHEMBL6949569 | 0.79 | CUL4A (0.45) | LMNATP53CYP1A2CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115776981-A | Material for organic electroluminescent device | 默克专利有限公司 | 2023-03-10 | — | — | CN | claimed |
| US-20220416164-A1 | NITROGEN-CONTAINING COMPOUNDS, ELECTRONIC ELEMENTS AND ELECTRONIC DEVICES | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2022-12-29 | — | — | US | claimed |
| CN-115087654-A | Material for organic electroluminescent device | 默克专利有限公司 | 2022-09-20 | — | — | CN | claimed |
| CN-114787173-A | Metal complexes | 默克专利有限公司 | 2022-07-22 | — | — | CN | claimed |
| CN-114516803-A | Fused ring compound and application thereof | 宁波卢米蓝新材料有限公司 | 2022-05-20 | — | — | CN | claimed |
| CN-111902409-A | Compound, material for organic electroluminescent element, and electronic device | 出光兴产株式会社 | 2020-11-06 | — | — | CN | claimed |
| CN-111788177-A | Spirobenzanthracene-fluorene derivatives and their use in organic electronic devices, display and lighting devices | 诺瓦尔德股份有限公司 | 2020-10-16 | — | — | CN | claimed |
| CN-111770922-A | Organic electronic device, display and lighting apparatus including the same | 诺瓦尔德股份有限公司 | 2020-10-13 | — | — | CN | claimed |
| CN-111683948-A | Phenanthroline compound and organic light emitting device including the same | 株式会社进雄产业 | 2020-09-18 | — | — | CN | claimed |
| CN-111564567-A | Organic light emitting element | 三星显示有限公司 | 2020-08-21 | — | — | CN | claimed |
| US-20050014801-A1 | Benzoisoselenazole derivatives with anti-inflammation, antivirus and antithrombosis activity and their use | PEKING UNIVERSITY (CN) | 2005-01-20 | — | — | US | claimed |
| EP-1422225-A1 | BENZOISOSELENAZOLE DERIVATIVES WITH ANTI-INFLAMMATION, ANTIVIRUS AND ANTI-THROMBOSIS ACTIVITY AND THEIR USE | Peking University (CN) | 2004-05-26 | — | — | EP | claimed |
| US-20020002177-A1 | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-01-03 | — | — | US | claimed |
| CN-1034569-C | ET (ENDOTHELIN) receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1997-04-16 | — | — | CN | claimed |
| CN-1145223-A | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1997-03-19 | — | — | CN | claimed |
| JP-H08510211-A | — | — | 1996-10-29 | — | — | JP | claimed |
| CN-1124923-A | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1996-06-19 | — | — | CN | claimed |
| EP-0699069-A4 | — | — | 1996-04-03 | — | — | EP | claimed |
| EP-0699069-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-03-06 | — | — | EP | claimed |
| WO-1994025013-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014801-A1 | Benzoisoselenazole derivatives with anti-inflammation, antivirus and antithrombosis activity and their use | SERPINC1, IL33, SERPINB1 | LMNA 2721/4885TP53 3461/4885CYP1A2 181/4885 |
| US-20220416164-A1 | NITROGEN-CONTAINING COMPOUNDS, ELECTRONIC ELEMENTS AND ELECTRONIC DEVICES | NPPA, NES, INA | LMNA 1408/4885TP53 3216/4885CYP1A2 1044/4885 |
| US-20020002177-A1 | Endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | LMNA 2153/4885TP53 4674/4885CYP1A2 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.